Oxford Biomedica (LON:OXB) Price Target Raised to GBX 380

Oxford Biomedica (LON:OXB) had its target price boosted by Deutsche Bank Aktiengesellschaft from GBX 250 ($3.35) to GBX 380 ($5.09) in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Oxford Biomedica Price Performance

LON OXB opened at GBX 381.50 ($5.11) on Tuesday. Oxford Biomedica has a 52 week low of GBX 164.29 ($2.20) and a 52 week high of GBX 394.50 ($5.28). The company has a current ratio of 3.19, a quick ratio of 1.67 and a debt-to-equity ratio of 143.20. The stock has a market cap of £401.87 million, a price-to-earnings ratio of -234.05 and a beta of 1.09. The company has a 50-day moving average price of GBX 349.59 and a two-hundred day moving average price of GBX 301.52.

Oxford Biomedica Company Profile

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.